Intrathecal Baclofen Trial as a Predictor of Long-Term Outcomes After Selective Dorsal Rhizotomy in Children with Spastic Cerebral Palsy
This study demonstrates that short-term clinical improvements observed during an intrathecal baclofen trial generally approximate long-term functional outcomes following selective dorsal rhizotomy in children with spastic cerebral palsy, suggesting the trial is a valuable tool for patient selection and expectation setting.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For many children born with cerebral palsy, the nervous system sends constant, too-strong signals that keep muscles tight and stiff. This condition, known as spasticity, makes walking difficult, causes pain, and can lead to permanent joint problems as the child grows. While physical therapy and medication can help manage these symptoms, they often cannot fix the underlying issue. For some children with severe spasticity, surgeons offer a procedure called selective dorsal rhizotomy. During this surgery, doctors carefully cut specific nerve fibers in the lower spine that are sending the wrong signals, permanently reducing the muscle tightness. However, the surgery is a major step with permanent effects, and it is not clear beforehand exactly how much a specific child will benefit. Because the results vary so much from one patient to another, doctors and families face a difficult question: how can they know if this permanent change will lead to the improved movement they hope for?
To answer this, a team of researchers at NYU Langone Health and The Valley Hospital looked back at the medical records of twenty-one children who had already undergone a specific testing process before their surgery. These children first received a temporary dose of a muscle-relaxing drug called baclofen directly into the fluid surrounding their spinal cord. This test, known as an intrathecal baclofen trial, acts like a reversible preview of what might happen if the nerves were permanently altered. The drug reduces muscle tightness for only a few hours, allowing doctors to see how the child's legs and walking pattern respond to the relief of spasticity without making any permanent changes. The researchers wanted to see if the improvements seen during this short, temporary test could accurately predict the long-term results the children would experience a year or more after the permanent surgery.
The study tracked these children at three distinct moments: before the drug was given, a few hours after the drug took effect, and at least one year after they had the surgery. The team measured how stiff the children's muscles were, how far they could move their legs, and how well they walked. They found that the changes observed during the short drug trial were remarkably similar to the changes seen after the surgery. For example, the average score measuring muscle stiffness dropped by two points during the drug trial and by two and a half points after the surgery. The difference between the two results was so small that it was not statistically significant, meaning the temporary test and the permanent surgery produced nearly the same level of improvement for the group as a whole.
This pattern held true for other measurements as well. When the children's straight leg raises were measured, the angle of the leg improved by ten degrees during the drug trial, and that same improvement was maintained a year after the surgery. The researchers also looked at how the children walked. While only twelve of the children were able to walk and were included in this specific part of the analysis, their walking scores improved by two points after the drug trial and by two and a half points after the surgery. Again, the gap between the temporary test and the permanent outcome was not large enough to be considered a real difference. The data suggests that for this group of children, the body's response to the temporary relief of muscle tightness was a very close mirror of what happened after the nerves were permanently cut.
The researchers also asked the parents and caregivers to share their own observations. The families reported that the improvements they saw during the drug trial felt very similar to the improvements they saw after the surgery. Most parents agreed that the trial helped them understand what to expect and was useful in making the decision to move forward with the operation. In fact, eighty-three percent of the caregivers said they would recommend this trial to other families considering the surgery. This feedback highlights that the test serves a dual purpose: it provides doctors with clinical data, but it also gives families a tangible experience of what the future might look like, helping them make an informed choice.
While the results are promising, the authors note that this study had a small number of participants and was conducted at a single medical center. They emphasize that while the group-level results were very similar, the study was not designed to prove that the trial can predict the outcome for every single individual child with perfect accuracy. The findings suggest that the trial is a valuable tool for setting expectations and helping with the decision-making process, but more research with larger groups is needed to confirm how well it works for each person. Ultimately, the study provides evidence that a temporary, reversible test can offer a clear and realistic glimpse into the potential benefits of a permanent surgical solution for children struggling with severe muscle stiffness.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.